EPS公司的竞争战略研究

发布时间：2018-04-23 12:09

本文选题：战略管理 + 医疗器械　；参考：《电子科技大学》2014年硕士论文

【摘要】：体外诊断属于医疗器械的子行业,约80%的临床诊断信息是通过体外诊断产品提供的,在临床医学中正发挥着越来越重要的作用。该行业近年来处于高速增长阶段,平均每年市场增长率超过15%。在丰厚利润的诱惑下,从事体外诊断企业的数量从最初的几十家增长至目前的500多家,市场竞争变得越来越残酷,国内企业受制于技术资金等短板,同质化竞争严重,价格战持续上演,市场一片红海。EPS公司是该行业众多企业中的一个,经过6年的发展,目前面临市场占有率低、产品缺乏竞争力等诸多问题,同时也面临大量的外部机会和威胁。为了适应新环境下的体外诊断行业发展,EPS公司有必要调整现有战略。基于此目的,本文对体外诊断行业及EPS公司进行了深度的分析,通过SWOT分析进行了战略的匹配与选择、并对战略实施与评价进行了探讨。本文首先从整体上对体外诊断行业做了一个系统的统计分析,得到了大量统计数据并对行业发展趋势及特点进行了总结。接着从政治、政策、法规,经济,社会、人口,科技等方面进行了外部环境的梳理,对所处的行业竞争环境进行了分析,得到了EFE矩阵。通过对企业内部基础设施、人力资源、财务分析、研发能力、营销能力、制造能力的分析,得到了EPS公司的优劣势以及IFE矩阵,最后通过SWOT分析得到了EPS公司的各种备选战略,通过比较分析得出应积极采取WO战略及SO战略,引入外部股权投资,实施后向一体化战略快速进入体外诊断试剂领域;通过前向一体化,与经销商共同合作建立EPS公司的销售团队;积极进入移动医疗领域,凭借特有的产品优势快速占领细分市场。最终就如何进行战略实施与评估做了初步的规划。
[Abstract]:Extracorporeal diagnosis belongs to the sub-profession of medical devices. About 80% of clinical diagnosis information is provided by in vitro diagnostic products, which is playing a more and more important role in clinical medicine. The industry has been at a high-speed growth stage in recent years, an average annual market growth rate of more than 15%. Lured by the huge profits, the number of enterprises engaged in in vitro diagnosis has increased from the initial dozens to more than 500 at present. The market competition has become more and more cruel, and domestic enterprises are constrained by technical funds and other shortcomings, and the homogeneous competition is serious. The price war continues to unfold. The market is a red sea. EPS is one of the many enterprises in the industry. After six years of development, it is facing many problems, such as low market share and the lack of competitiveness of its products. At the same time, it also faces a large number of external opportunities and threats. It is necessary for EPS to adjust its existing strategy in order to adapt to the development of in vitro diagnosis industry under the new environment. Based on this purpose, this paper makes a deep analysis of the in vitro diagnosis industry and EPS Company, and through the SWOT analysis to carry on the strategy matching and the choice, and has carried on the discussion to the strategy implementation and the appraisal. This paper firstly makes a systematic statistical analysis on the in vitro diagnosis industry, obtains a large number of statistical data and summarizes the development trend and characteristics of the industry. Then the external environment of politics, policy, law, economy, society, population, science and technology is combed, and the competition environment of the industry is analyzed, and the EFE matrix is obtained. Through the analysis of internal infrastructure, human resources, financial analysis, R & D capability, marketing capability and manufacturing capability, the advantages and disadvantages of EPS Company and the IFE matrix are obtained. Finally, through SWOT analysis, various alternative strategies of EPS Company are obtained. Through comparative analysis, it is concluded that WO strategy and so strategy should be actively adopted, external equity investment should be introduced, and backward integration strategy should be implemented rapidly into the field of external diagnostic reagents. Work with dealers to establish EPS sales team; actively enter the mobile medical field, with unique product advantages to quickly occupy the market segment. Finally, it makes a preliminary plan on how to carry out the strategy implementation and evaluation.
【学位授予单位】：电子科技大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F426.46;F272

【共引文献】